Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Nature · 897 citations
https://doi.org/10.1038/s41586-018-0810-y
M
Marco Skardelly
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
118
Papers
3.5K
Citations
29
h-index
67
i10-index
Marco Skardelly is an academic researcher from University Children's Hospital Tübingen. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Meningioma and schwannoma management & Neurofibromatosis and Schwannoma Cases. The author has an h-index of 29, co-authored 101 publications.
ORCID: 0000-0002-3870-6872Papers by this author
worksATRX immunostaining predicts IDH and H3F3A status in gliomas
2016 · Acta Neuropathologica Communications · 118 citations
https://doi.org/10.1186/s40478-016-0331-6
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
2016 · Diagnostic Pathology · 110 citations
https://doi.org/10.1186/s13000-016-0506-2
The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy
2020 · Neurosurgical Review · 50 citations
https://doi.org/10.1007/s10143-020-01428-7
Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study
2019 · European Journal of Radiology · 23 citations
https://doi.org/10.1016/j.ejrad.2019.01.014
COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake
2019 · Acta Neuropathologica Communications · 20 citations
https://doi.org/10.1186/s40478-019-0760-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat